Vetasi is delighted to announce that we have won a contract with GW Pharmaceuticals to implement Maximo across their UK sites.
James Prior, MD Vetasi, said; “We are looking forward to working in partnership with GW Pharmaceuticals to achieve their goals, and ensure that the new Maximo system provides them with real time visibility of their assets and drives continuous business improvement”.
Drawing on Vetasi’s wide experience in the pharmaceuticals and life sciences sectors, we will collaborate with GW Pharmaceuticals to meet their specific requirements, whilst utilising the best practices of Maximo and supporting software.
NOTES TO EDITORS
For more information, contact:
T: 08434 610061
Vetasi is an international consultancy specialising in solutions for Work & Enterprise Asset Management. Working with leading companies across the FM, utilities, transportation, oil and gas, life sciences, manufacturing and mining industries to significantly improve asset performance and maximise their return on investment. www.vetasi.com
About GW Pharmaceuticals
GW Pharmaceuticals (GW) is a pioneering UK-based biopharmaceutical company that over the last 20 years has established a world-leading position in cannabinoid science and medicines. GW’s mission is to transform the lives of seriously ill patients with significant unmet need through developing and delivering rigorously tested cannabis-derived pharmaceutical medicines with documented safety and efficacy profiles, approved by regulators and manufactured to the highest standards. https://www.gwpharm.co.uk/